NMP22联合尿脱落细胞学检测在膀胱癌术后复发监测中的价值  

The Value of Urinary Nuclear Matrix Protein 22 and Urine Cytology in the Diagnosis of Postoperative Recurrence of Bladder Cancer

作　　者：刘民[1] 孙志广[1] 王小波[2] 张廷继[2] 

机构地区：[1]沧州市中心医院泌尿外科,河北沧州061001 [2]天津市人民医院泌尿外科

出　　处：《临床泌尿外科杂志》2009年第12期911-913,共3页Journal of Clinical Urology

摘　　要：目的：探讨尿核基质蛋白22（NMP22）联合尿脱落细胞学榆测对膀胱移行细胞癌诊断及术后复发监测中的应用价值。方法：采用酶联免疫法（EI。ISA）检测60例膀胱癌者、20例非膀胱癌者、20例健康志愿者尿中NMP22水平，并同时行尿脱落细胞学检查，并对结果进行比较。结果：膀胱癌者NMP22平均为35．6×10^3U／L，高于非膀胱癌者（7．8×10^3U／L）和健康志愿者（7．2×10^3U／L，P〈0．05）；膀胱癌复发患者（31．5×10^3U／L）高于未复发患者（8．O×10^3U／L，P〈0．05）；膀胱癌者NMP22的敏感性高于尿脱落细胞学，而其特异性低于尿脱落细胞学。结论：尿NMP22对膀胱移行细胞癌具有高灵敏度和无创伤性，是检测膀胱移行细胞癌的有效标志物；联合尿细胞学检查可进一步提高膀胱癌术后复发的诊断率。Objective：To evaluate the value of urinary nuclear matrix protein 22 （NMP22） and urine cytology in the diagnosis of bladder transitional cell carcinoma and postoperative recurrence of bladder cancer. Methods： Urinary NMP22 levels were detected in 60 cases of bladder cancer, 20 cases of urinary non bladder cancer disease, 20 cases of healthy volunteers using enzyme-linked immunosorbent assay （ELISA）, and urine cytology were detected at the same time, and the results were compared. Results：The average NMP22 of bladder cancer group was 35.6×10^3U/L, significantly higher than the non bladder cancer, urinary tract diseases group （7.8×10^3U/L） and healthy volunteers group （7.2×10^3U/L, P〈0. 05）; recurrence of bladder cancer group cases （31.5×10^3U/L） was higher than patients with no recurrence （8.0×10^3U/L, P〈0.05）. In bladder cancer group, the sensitivity of NMP22 is higher than urine cytology, and its specific is Lower than urine cytology. Conclusions：The detection of urinary NMP22 is highly sensitive and non-invasive to bladder transitional ceil carcinoma, It can be used as an effective marker in detection of bladder transitional cell carcinoma, urine cytology can be combined to further improve the diagnosis of postoperative recurrence of bladder cancer.

关 键 词：膀胱肿瘤 移行细胞癌 核基质蛋白22 尿细胞学 

分 类 号：R737.14[医药卫生—肿瘤]